Trilipix

(choline fenofibrate)

ApprovedSmall molecule

AbbVie

Trilipix is one of 32 small molecule programs targeting Atherosclerosis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

AtherosclerosisActive, not recruiting

AtherosclerosisApproved

Active, not recruiting

Competition

Competitive Landscape

165 competitors in Atherosclerosis

#DrugCompanyPhaseTrials

Avandia

Alnylam Pharmaceuticals

Phase 3

3 2

Estrace

Novo Nordisk

Phase 3

2 3

Colcrys

Alnylam Pharmaceuticals

Phase 3

1 4

Glucotrol

Pfizer

Phase 3

1 5

Actemra

Roche

Phase 3

1 6

Brilinta

AstraZeneca

Phase 3

1 7

Altoprev

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

2 8

Zontivity

Akero Therapeutics

Phase 3

2 9

Colestid

Pfizer

Phase 3

2 10

Trilipix

AbbVie

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Atherosclerosis

NCT05365425

Clinical

Trials by Indication[1]

Cholesterol1 trial

ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study

Completed·RRadiant Research·Phase 1/2·NCT00673881·25 enrolled

Macular Edema1 trial

Effect of Choline Fenofibrate (SLV348) on Macular Edema

Completed·AAbbott Products·Phase 2·NCT00683176·110 enrolled

Atherosclerosis1 trial

Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

Recruiting·SSeoul National University Bundang Hospital·Phase 4·NCT05365425·56 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 15, 2008

TRILIPIX

NDA NDA022224

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for choline fenofibrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — choline fenofibrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for choline fenofibrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA022224). U.S. Food & Drug Administration.
[5]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AbbVie

Trilipix

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Cholesterol1 trial

Macular Edema1 trial

Atherosclerosis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News